• Dabigatran Safety: Lessons from a 2019 Review

  2026-09-29

  This review reframed Dabigatran safety around real-world adverse-event reports rather than anticoagulant efficacy alone. Its synthesis highlights bleeding, gastrointestinal and esophageal injury, allergic reactions, organ impairment, and acute coronary events, while proposing risk assessment and management considerations for clinical practice.

• RNA Pol II Loss Activates Apoptosis Beyond Transcription

  2026-09-28

  Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic signaling program rather than through passive depletion of mRNA and protein. Their identification of the Pol II degradation-dependent apoptotic response (PDAR) separates loss of RNA Pol IIA from loss of transcription and provides a framework for interpreting how diverse anticancer drugs can trigger mitochondrial cell death.

• Thiamet G and Placental Ferroptosis Assay Logic

  2026-09-28

  Explore how Thiamet G, an O-GlcNAcase inhibitor, can help interrogate O-GlcNAc signaling in trophoblast ferroptosis. A new preeclampsia study connects HUWE1 modification to TfR1 turnover, iron uptake, and syncytialization—and offers practical guidance for designing causal assays.

• Cy5 TSA Fluorescence System Kit in Plaque Biology

  2026-09-27

  The Cy5 TSA Fluorescence System Kit offers a spatially focused way to investigate inflammatory signals in atherosclerotic tissue. This article connects tyramide chemistry to a recent NLRP3 study while clarifying what amplified staining can—and cannot—show about disease mechanisms.

• Mapping Metastatic Cell Identity with Cy5 TSA

  2026-09-26

  Metastatic head and neck cancer research increasingly depends on resolving where cellular identity changes occur—not only which genes change. This article connects recent HNSCC single-cell findings to spatial validation strategies, explaining how HRP-driven Cy5 tyramide deposition can help researchers investigate scarce targets while preserving tissue context.

• Tigecycline Workflows for Resistance Research

  2026-09-25

  Use Tigecycline as a controlled phenotypic probe alongside carbapenemase genotyping—not as a substitute for resistance-gene analysis. This workflow connects susceptibility testing with the plasmid-transfer findings in carbapenem-resistant Enterobacter cloacae while flagging the interpretation limits that matter at the bench.

• RBM28 Links Nucleolar Stress to p53 Suppression

  2026-09-25

  The study identifies RBM28 as a cancer-associated regulator that can move from the nucleolus into the nucleoplasm, bind p53, and suppress its transcriptional activity. It connects chemotherapy-associated stress and likely Chk1/2-dependent RBM28 phosphorylation at Ser122 to this change in localization, offering a mechanistic framework for studying nucleolar stress and p53 function.

• (S)-(+)-Ibuprofen: COX Inhibitor Evidence

  2026-09-24

  (S)-(+)-Ibuprofen is a stereochemically defined COX inhibitor for inflammation pathway research and related assay development. Product-reported enzyme and ecotoxicity values are useful starting points, but missing assay conditions limit direct comparisons.

• Actinomycin D: Practical Assay Design for Reliable Data

  2026-09-24

  A scenario-driven guide to using Actinomycin D in viability, proliferation, and mRNA stability experiments, with practical guidance on dosing, controls, and interpretation. It summarizes the documented handling profile of APExBIO SKU A4448 and links experimental decisions to relevant evidence.

• Tacrolimus (FK506) in Stress–Immune Signaling

  2026-09-23

  Tacrolimus (FK506) is an FKBP12-dependent calcineurin inhibitor used to investigate T-cell activation and cytokine signaling pathway modulation. It provides a tool for transplantation immunology research and immune response suppression, but it does not directly test the AMPK–SQSTM1–NRF2 feedback loop described in recent metabolic-stress research.

• Gefitinib (ZD1839) for EGFR Barrier Studies

  2026-09-23

  Use Gefitinib (ZD1839) to test whether EGFR signaling drives blue-light-induced skin barrier dysfunction, while retaining a validated workflow for cancer-cell signaling, proliferation, and resistance studies. This guide connects phosphoprotein measurements with functional barrier and viability readouts, plus practical controls for reproducible EGFR pathway inhibition.

• Pam3CSK4 TFA: Practical TLR1/2 Workflows

  2026-09-22

  Use Pam3CSK4 TFA as a defined TLR1/2 agonist to separate receptor-specific innate signaling from the complexity of whole-pathogen exposure. The workflow connects controlled cytokine stimulation with translational questions such as maternal IL-17A variation and neonatal Group B Streptococcus risk.

• From Hippo Biology to Spatial Assay Strategy

  2026-09-22

  A translational framework for using localized Cy5 tyramide amplification to interrogate Hippo-regulated hepatobiliary maturation, regenerative states, and low-abundance spatial biomarkers.

• KN-62: Applied CaMKII Workflows

  2026-09-21

  KN-62 enables pathway-focused experiments that connect calcium entry, CaMKII activity, secretion, metabolism, and cell-cycle control. This guide translates the compound’s biochemical profile into practical assay workflows while showing how the latest social-memory findings can inform neuronal assay design without overstating the evidence.

• Tigecycline as a Resistance-Transmission Assay Tool

  2026-09-21

  Tigecycline is more than a glycylcycline antibiotic comparator: it can help researchers interpret phenotype–genotype relationships in mobile carbapenemase systems. This article translates Guangdong CREC transmission data into a rigorous, orthogonal assay framework while defining the limits of that application.

555 records 3/37 page Previous Next 12345 下5页 Last page